German specialty chemicals group Evonik Industries raised its full-year profit guidance on Friday after second-quarter results comfortably exceeded analyst expectations, signaling that cost-cutting initiatives and operational improvements are beginning to bear fruit.
The company now expects full-year adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) in the range of €2.0 billion to €2.2 billion, up from the previous guidance of €1.7 billion to €1.9 billion. The revised forecast reflects stronger-than-anticipated performance across the company's Specialty Additives and Performance Materials divisions.
Q2 Performance
Preliminary second-quarter results released alongside the guidance upgrade show adjusted EBITDA of approximately €596 million for the April-June period, surpassing the consensus analyst estimate of €567 million. Revenue for the quarter came in at €3.82 billion, up 4.3% year-over-year, driven by higher volumes and improved pricing in key end markets including coatings, adhesives, and pharmaceuticals.
Evonik's EBITDA margin improved to 15.6% in Q2, compared to 13.8% in the same period last year, reflecting the impact of the company's "Next Generation Evonik" restructuring program, which has delivered €180 million in annualized cost savings ahead of schedule. The program, announced in early 2025, targets €350 million in structural cost reductions by the end of 2027 through streamlining of administrative functions, optimization of the production footprint, and procurement efficiencies.
German Chemical Sector Context
Evonik's positive update stands out in a German chemicals sector that has faced headwinds from elevated energy costs, subdued industrial demand, and the broader macroeconomic uncertainty weighing on European manufacturing. The VDMA Purchasing Managers' Index for German chemicals remained below the 50-breakeven mark in May at 48.3, indicating continued contraction in the sector.
However, there are emerging signs that the trough may have passed. BASF, Germany's largest chemical company by revenue, noted in its recent investor day that destocking by customers appears to be largely complete and that order book visibility has improved for the second half of the year. Evonik's results provide the most concrete evidence yet that operational improvements can deliver earnings growth even in a challenging macro environment.
Market Reaction
Shares of Evonik surged 6.8% on the Frankfurt Stock Exchange following the announcement, outperforming the DAX index which was up 0.3% on the day. The stock has now gained 22% year-to-date, outpacing the broader European chemicals sector, which has risen approximately 12% over the same period.
Analysts at Morgan Stanley upgraded the stock to "Overweight" from "Equal-weight," raising their price target to €24.50 from €20.00. In a note to clients, they highlighted that "Evonik is demonstrating that structural cost actions can drive margin expansion independent of the macro cycle, a thesis that should command a valuation premium relative to peers."
Deutsche Bank maintained its "Buy" rating, noting that the upgraded guidance may still prove conservative. "Our channel checks suggest that the volume recovery in Q2 has continued into July, and the €2.0-€2.2 billion range provides room for further upside if macro conditions stabilize," the bank's analyst wrote.
Broader Implications
Evonik's performance is closely watched as a bellwether for the European specialty chemicals and broader industrial sector. The company's exposure to end markets including automotive, construction, healthcare, and consumer goods makes its results a useful gauge of industrial activity across the continent.
The upgraded guidance adds to a growing body of evidence that European industrial companies are successfully navigating the high-cost, low-growth environment through operational improvements. However, the sustainability of these improvements depends on whether the macro backdrop cooperates. The elevated European Central Bank rate environment and persistent inflation in services continue to pose risks to demand recovery in the second half of the year.
Evonik will release its full second-quarter financial report on August 7, which will include further details on divisional performance and management's outlook for the remainder of 2026. The company's annual Capital Markets Day, scheduled for November, will provide an update on the "Next Generation Evonik" program and medium-term financial targets.